Recent Quotes (30 days)

You have no recent quotes
chg | %

Hemostemix Inc  

(Public, CVE:HEM)   Watch this stock  
Find more results for CVE:TIK.P
0.000 (0.00%)
Oct 8 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.58 - 1.25
Open     -
Vol / Avg. 80.00/8,128.00
Mkt cap 46.06M
P/E     -
Div/yield     -
EPS -0.06
Shares 65.80M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -145.06% -207.18%
Return on average equity -182.75% -243.48%
CDP Score - -


1015 4 St SW Suite 730
+1-647-9198820 (Phone)

Website links


Hemostemix Inc. is a clinical-stage biotechnology company that develops and commercializes blood-derived cell therapies for medical conditions. The company's lead product ACP-01 is an autologous, blood-derived cell product that is in phase II clinical trial used for the treatment of critical limb ischemia. The Company is also developing other cell products, such as bone cell precursors (BCPs), myocardial cell precursors (MCPs), and neural cell precursors (NCPs). The Company operates a research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona, Israel.